BioVie Inc Stock News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to shareholders. If you currently own BioVie stock and acquired shares on or before December 7, 2022, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-...

BioVie Inc. - Special Call Company Participants Cuong Viet Do - President, CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with RedChip Companies.

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025.

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit con...

Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission

Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation